Company news
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) news
Every Cumberland Pharmaceuticals Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
August 4, 2026
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
July 28, 2026
CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE
July 13, 2026
Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex
July 1, 2026
Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
June 26, 2026
Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis
June 2, 2026
CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA
May 28, 2026
CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
May 5, 2026
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
April 28, 2026
Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex
April 23, 2026
CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE
April 16, 2026
Cumberland Pharmaceuticals Launches New Sancuso Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting
March 18, 2026
Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting
March 17, 2026
Cumberland Pharmaceuticals : Annual Report for Fiscal Year Ending 12-31, 2025 (Form 10-K)
March 9, 2026
CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH
March 3, 2026
CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®
February 25, 2026
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE
February 24, 2026
Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program
February 4, 2026
CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT
December 8, 2025
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement
December 1, 2025
CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH
November 4, 2025
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE
October 28, 2025
RedHill Biopharma Receives Nasdaq Staff Determination Notification
October 22, 2025
CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
October 20, 2025
CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.
October 13, 2025
CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO
October 1, 2025
TABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA
September 29, 2025
Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date
August 5, 2025
CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK
August 4, 2025
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE
July 29, 2025
Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
June 23, 2025
NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS
May 27, 2025
CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH
May 13, 2025
Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025
May 6, 2025
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE
April 29, 2025
FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference
March 19, 2025
Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth
March 4, 2025
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS
February 25, 2025
VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA
February 18, 2025
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease
February 4, 2025
FDA APPROVES ACETADOTE® sNDA
December 9, 2024
Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update
November 7, 2024
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
November 6, 2024
Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024
August 6, 2024
Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update
May 7, 2024
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS
April 30, 2024
Cumberland Pharmaceuticals Reports Annual 2023 Financial Results
March 5, 2024
Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results
November 7, 2023
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS
October 31, 2023
Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023
August 8, 2023